The key highlights of the report include:

• According to IIR, the acquisition of Next Generation CAR-T Platform from the University of Pennsylvania (Upenn) could be a potential game changer. PTX intends to use these licences and technology to build OmniCAR, a next generation cell therapy platform.
• The acquisition compliments their collaboration with Carina Biotech to develop Carina’s CAR-T technologies for the treatment of solid tumours.

• IIR expects that  Prescient Therapeutics will seek to deliver a proof of concept for the OmniCAR Platform swiftly – likely on known and validated targets in blood cancers first, before moving on to solid cancers. 
• “The recent collaboration with Carina Biotech provides a convenient pathway for testing on new solid tumour targets,” states the report. 

• The company generated a loss of $1.7m in 1H’20, a slight increase from the $1.6m loss in 1H’19. 
• At 31 March 2020, the company had $8.2m in cash reserves. 
• At 31 March, the company had sufficient capital to operate for a further 18 months.

• IRR states that ‘PTX provides a unique investment opportunity on the domestic market given the company is the only ASX-listed company with UIR technology.’
• The report also quotes ‘We acknowledge that the OmniCAR platform is in the early stages of development and the development of the platform will encounter its own unique challenges.’